ST-Segment Elevation Infarction After TAVR: Problems in Every Aspect

For interventional cardiologists, treating an ST-segment elevation infarction in a patient with transcatheter aortic valve replacement (TAVR) is challenging in many ways. Longer door-to-balloon times and higher rates of primary angioplasty failure than in the general population are translated into very high short- and mid-term mortality.

Infarto con supradesnivel del ST post TAVI: problemas en todos los sentidos

This multicenter study, recently published in JACC, included 118 patients admitted with ST-segment elevation infarction at a mean of 225 days (range: 9 to 680 days) after valvular implantation.

The characteristics of post-TAVR infarction patients who underwent primary angioplasty were compared with 439 patients without prior TAVR who underwent primary angioplasty in the same time period.

The mean door-to-balloon time was higher for TAVR patients (40 minutes vs. 30 minutes [p = 0.003]). Procedure time, fluoroscopy time, radiation dose, and contrast volume were significantly higher for the TAVR population (p < 0.01 for all).

The primary angioplasty failure rate was 4x higher in those with implanted valves (16.5% vs. 3.9%; p < 0.001), including 5 patients whose culprit artery could not be catheterized.

In-hospital mortality was 25.4%, while mid-term mortality (7 months) was as high as 42.4%.

Renal impairment and Killip class >II were 3x more frequent in patients with previous TAVR (hazard ratio [HR]: 3.02; p = 0.004; and HR: 2.74; p = 0.004, respectively).


Read also: New Cardiac Failure Diagnoses after COVID-19 Infection.


All these more frequent events in the TAVR population explain the higher short- and mid-term mortality.

Conclusion

ST-segment elevation infarctions in patients with prior TAVR are associated with much higher short- and mid-term mortality. Longer door-to-balloon times and higher primary angioplasty failure rates are due, partly, to difficulties accessing coronary arteries.

Original Title: ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement.

Reference: Laurent Faroux et al. J Am Coll Cardiol. 2021 May 4;77(17):2187-2199. doi: 10.1016/j.jacc.2021.03.014.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...